Drug Trial News

RSS

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.

5 May 2015

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

A new vaccine has proven almost completely effective in preventing shingles (disease medical name: herpes zoster), an extremely painful nerve infection which affects a third of Australians; most over the age of 50.

1 May 2015

New research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D

Eleven IFPMA member companies are involved in the development of new antibiotics. There are currently 34 antibacterial compounds in development (19 molecules and 15 vaccines). Eight compounds are undergoing the final stages of demonstrating their efficacy, quality, and safety (phase 3 clinical trials)...

30 Apr 2015

Keynote 24 study explores investigational approach to treating lung cancer

Lung cancer impacts the lives of millions of people worldwide. In nearly 40 percent of people diagnosed with lung cancer, it has metastasized, or spread to other areas of the body, making it difficult to treat. Immunotherapy is a type of therapy that uses the body's own immune system to help fight cancer. Immunotherapy may help the body's immune system target cancer cells.

30 Apr 2015

Ortho-ATI™ long term study showing effectiveness for tennis elbow published in prestigious American Journal of Sports Medicine

The publication provides evidence of the durability and long term positive effect of Orthocell’s Ortho-ATI™ tendon regeneration treatment for degenerate tendon injuries...

30 Apr 2015

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

DelMar Pharmaceuticals, Inc., today announced that it will be presenting new data related to the development of lead product candidate VAL-083 (dianhydrogalactitol) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2, 2015, in Chicago, Illinois.

30 Apr 2015

OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

OncoGenex Pharmaceuticals, Inc. announced today it has filed an amendment with the U.S. Food and Drug Administration, as well as initiated filing with regulatory agencies in other countries, to amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC).

30 Apr 2015

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit.

29 Apr 2015

Ascendis reports results from Phase 1 single ascending dose study of TransCon Treprostinil

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its TransCon technology to address significant unmet medical needs, announced today that its Phase 1 single ascending dose study of TransCon Treprostinil produced dose-dependent increases in plasma treprostinil levels in-line with expectations.

29 Apr 2015

Will new hepatitis C treatments strain payers’ budgets? An interview with Dr Chhatwal

Our analysis shows that these drugs would not save overall healthcare money, but would add to the budget. When something is cost effective, it does not necessarily mean it is going to save money. It essentially implies that we're willing to spend additional money to gain additional benefits...

28 Apr 2015

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis.

27 Apr 2015

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence.

27 Apr 2015

Multicentre study provides hope for malaria therapy with just one dose

Approximately 584,000 people worldwide die of malaria each year. The epidemic strongly associated with poverty claims most of its victims in Africa, where it particularly affects the weakest, children and pregnant women. Current therapies have to be taken over several days to be effective against malaria.

25 Apr 2015

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling.

25 Apr 2015

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis plc today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA).

25 Apr 2015

Asthma breakthrough: potential cause and corrective treatment are identified

A paper published yesterday in Science Translational Medicine reports that the root cause of asthma has been found and a potential treatment to reverse all symptoms has been proposed...

24 Apr 2015

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.

24 Apr 2015

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai.

24 Apr 2015

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).

24 Apr 2015

Recommended alcoholic hepatitis treatments fail to increase patients' survival

The main drugs used to treat alcoholic hepatitis are not effective at increasing patients' survival, a major study has found. In a trial of over 1,000 patients, prednisolone and pentoxifylline, treatments recommended in international guidelines, did not achieve a statistically significant reduction in mortality after 28 days, 90 days or a year.

24 Apr 2015

Drug Trial News

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

New research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D

Keynote 24 study explores investigational approach to treating lung cancer

Ortho-ATI™ long term study showing effectiveness for tennis elbow published in prestigious American Journal of Sports Medicine

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Ascendis reports results from Phase 1 single ascending dose study of TransCon Treprostinil

Will new hepatitis C treatments strain payers’ budgets? An interview with Dr Chhatwal

Can-Fite announces favorable data from further analysis of CF101 Phase II/III study in patients with psoriasis

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Multicentre study provides hope for malaria therapy with just one dose

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Asthma breakthrough: potential cause and corrective treatment are identified

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Recommended alcoholic hepatitis treatments fail to increase patients' survival

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News